OnKure Therapeutics (OKUR) Financials

OnKure Therapeutics logo
$2.70 -0.06 (-2.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.70 +0.00 (+0.19%)
As of 11/20/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for OnKure Therapeutics

Annual Income Statements for OnKure Therapeutics

This table shows OnKure Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-19 -40 -52 -35 -53 -60
Consolidated Net Income / (Loss)
-19 -40 -52 -35 -53 -60
Net Income / (Loss) Continuing Operations
-19 -40 -52 -35 -53 -60
Total Pre-Tax Income
-20 -40 -52 -35 -53 -60
Total Operating Income
-20 -40 -54 -37 -54 -63
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
20 40 54 37 54 63
Selling, General & Admin Expense
3.61 12 16 4.82 11 15
Research & Development Expense
16 28 38 32 44 48
Total Other Income / (Expense), net
0.00 0.05 1.89 1.62 1.71 3.43
Interest Expense
- - - -1.62 -1.71 -3.43
Basic Earnings per Share
($9.60) ($2.19) ($2.12) ($124.41) ($15.28) ($4.40)
Weighted Average Basic Shares Outstanding
2.03M 18.14M 24.50M 283.82K 3.45M 13.52M
Diluted Earnings per Share
($9.60) ($2.19) ($2.12) ($124.41) ($15.28) ($4.40)
Weighted Average Diluted Shares Outstanding
2.03M 18.14M 24.50M 283.82K 3.45M 13.52M
Weighted Average Basic & Diluted Shares Outstanding
- 24.46M 25.11M 33.42M 13.44M 13.67M

Quarterly Income Statements for OnKure Therapeutics

This table shows OnKure Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-9.54 -14 -12 -17 -16 -15 -15 -14 -15 -15 -18
Consolidated Net Income / (Loss)
-9.54 -14 -12 -17 -16 -15 -15 -14 -15 -15 -18
Net Income / (Loss) Continuing Operations
-9.54 -14 -12 -17 -16 -15 -15 -14 -15 -15 -18
Total Pre-Tax Income
-9.54 -14 -12 -17 -16 -15 -15 -14 -15 -15 -18
Total Operating Income
-9.83 -14 -12 -19 -17 -16 -16 -14 -16 -17 -19
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
9.83 14 12 19 17 16 16 14 16 17 19
Selling, General & Admin Expense
1.27 3.59 1.40 4.34 3.99 3.71 3.59 3.41 3.91 4.29 4.29
Research & Development Expense
8.57 11 10 14 13 13 12 11 12 13 15
Total Other Income / (Expense), net
0.30 0.20 -0.04 1.26 1.08 0.93 0.80 0.62 0.46 1.55 1.51
Interest Expense
- -0.20 0.04 - -1.08 -0.93 -0.80 - -0.46 -1.55 -1.51
Basic Earnings per Share
($30.37) ($44.82) ($36.55) $96.46 ($1.19) ($1.14) ($1.09) ($0.98) ($1.11) ($0.31) ($0.36)
Weighted Average Basic Shares Outstanding
314.02K 315.48K 316.14K 3.45M 13.42M 13.51M 13.53M 13.52M 13.67M 49.87M 49.93M
Diluted Earnings per Share
($30.37) ($44.82) ($36.55) $96.46 ($1.19) ($1.14) ($1.09) ($0.98) ($1.11) ($0.31) ($0.36)
Weighted Average Diluted Shares Outstanding
314.02K 315.48K 316.14K 3.45M 13.42M 13.51M 13.53M 13.52M 13.67M 49.87M 49.93M
Weighted Average Basic & Diluted Shares Outstanding
33.42M 33.43M 13.34M 13.44M 13.51M 13.53M 13.55M 13.67M 40.40M 40.50M 40.50M

Annual Cash Flow Statements for OnKure Therapeutics

This table details how cash moves in and out of OnKure Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
36 71 -105 18 81 -52
Net Cash From Operating Activities
-19 -38 -47 -35 -51 -52
Net Cash From Continuing Operating Activities
-19 -38 -47 -35 -51 -52
Net Income / (Loss) Continuing Operations
-19 -40 -52 -35 -53 -60
Consolidated Net Income / (Loss)
-19 -40 -52 -35 -53 -60
Depreciation Expense
0.04 0.05 0.09 0.42 0.46 0.45
Amortization Expense
-0.02 0.20 -0.82 0.14 0.35 0.38
Non-Cash Adjustments To Reconcile Net Income
0.40 4.34 3.93 -0.01 4.70 11
Changes in Operating Assets and Liabilities, net
0.51 -2.80 1.40 0.22 -3.95 -4.24
Net Cash From Investing Activities
7.38 -23 -58 -0.25 16 -0.05
Net Cash From Continuing Investing Activities
7.38 -23 -58 -0.25 16 -0.05
Purchase of Property, Plant & Equipment
-0.02 -0.20 -0.35 -0.25 -0.05 -0.05
Sale and/or Maturity of Investments
7.40 8.23 44 0.00 16 0.00
Net Cash From Financing Activities
47 132 0.47 53 116 0.16
Net Cash From Continuing Financing Activities
47 132 0.47 53 116 0.16
Repayment of Debt
- - - 0.00 -0.14 0.00
Repurchase of Common Equity
- - 0.00 0.00 -4.33 -0.04
Issuance of Debt
- - - 0.00 6.00 0.00
Issuance of Common Equity
0.00 85 0.47 0.07 59 0.24
Other Financing Activities, net
0.09 - - 0.00 56 -0.04
Cash Interest Paid
- - - 0.00 0.00 0.00

Quarterly Cash Flow Statements for OnKure Therapeutics

This table details how cash moves in and out of OnKure Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-11 -0.62 -11 103 -14 -13 -13 -11 133 -26 -15
Net Cash From Operating Activities
-11 -6.47 -11 -23 -14 -13 -13 -12 -13 -10 -13
Net Cash From Continuing Operating Activities
-11 -6.47 -11 -23 -14 -13 -13 -12 -13 -10 -13
Net Income / (Loss) Continuing Operations
-9.54 -14 -12 -17 -16 -15 -15 -14 -15 -15 -18
Consolidated Net Income / (Loss)
-9.54 -14 -12 -17 -16 -15 -15 -14 -15 -15 -18
Depreciation Expense
0.11 0.11 0.12 0.12 0.12 0.12 0.11 0.10 0.10 0.09 0.05
Amortization Expense
0.04 0.04 0.17 0.11 0.09 0.10 0.10 0.10 0.10 0.10 0.09
Non-Cash Adjustments To Reconcile Net Income
0.06 1.76 0.18 2.71 2.75 2.78 3.23 2.49 2.78 3.02 3.11
Changes in Operating Assets and Liabilities, net
-1.30 5.76 0.44 -8.84 -1.04 -0.87 -1.77 -0.70 -0.76 1.79 1.51
Net Cash From Investing Activities
-0.01 -0.01 -0.02 16 -0.02 -0.01 -0.01 -0.01 -0.01 -9.87 -1.97
Net Cash From Continuing Investing Activities
-0.01 -0.01 -0.02 16 -0.02 -0.01 -0.01 -0.01 -0.01 -9.87 -1.97
Purchase of Property, Plant & Equipment
-0.01 -0.01 -0.02 -0.02 -0.02 -0.01 -0.01 -0.01 -0.01 -0.00 -0.03
Purchase of Investments
- - - - - - - - - - -2.94
Net Cash From Financing Activities
0.01 5.87 0.01 110 -0.08 - - 0.24 146 -5.38 -0.01
Net Cash From Continuing Financing Activities
0.01 5.87 0.01 110 -0.08 - - 0.24 146 -5.38 -0.01
Repayment of Debt
- - - - 0.00 - - - 0.00 -9.58 -0.01

Annual Balance Sheets for OnKure Therapeutics

This table presents OnKure Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
55 154 108 36 115 62
Total Current Assets
55 154 106 34 113 61
Cash & Equivalents
54 125 20 30 111 59
Short-Term Investments
0.00 23 81 0.00 - 0.00
Prepaid Expenses
1.41 6.06 5.18 3.89 2.24 1.79
Plant, Property, & Equipment, net
0.07 0.21 0.45 1.43 1.03 0.62
Total Noncurrent Assets
0.13 0.08 1.38 0.54 0.88 0.66
Other Noncurrent Operating Assets
0.13 0.00 1.38 0.54 0.88 0.66
Total Liabilities & Shareholders' Equity
55 154 108 36 115 62
Total Liabilities
4.62 6.81 8.21 7.75 11 5.93
Total Current Liabilities
4.58 6.20 7.12 7.29 11 5.92
Accounts Payable
0.91 2.02 1.89 3.42 9.99 5.37
Other Current Liabilities
- 0.00 0.40 0.21 0.54 0.55
Total Noncurrent Liabilities
0.04 0.61 1.09 0.47 0.55 0.01
Other Noncurrent Operating Liabilities
- 0.17 1.06 0.47 0.55 0.01
Commitments & Contingencies
- - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-42 147 100 -102 104 56
Total Preferred & Common Equity
-42 147 100 -102 104 56
Total Common Equity
-42 147 100 -102 104 56
Common Stock
2.84 232 237 0.21 259 270
Retained Earnings
-45 -85 -137 -102 -155 -214
Accumulated Other Comprehensive Income / (Loss)
0.00 0.03 -0.04 0.00 - 0.00

Quarterly Balance Sheets for OnKure Therapeutics

This table presents OnKure Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
130 85 79 78 100 86 73 199 179 167
Total Current Assets
129 84 78 77 98 85 72 197 178 166
Cash & Equivalents
12 20 36 61 97 83 70 192 167 151
Short-Term Investments
114 62 41 16 0.00 0.00 0.00 0.00 9.88 12
Prepaid Expenses
3.16 1.09 1.32 0.33 1.51 1.18 1.20 5.38 1.29 2.29
Plant, Property, & Equipment, net
0.53 0.10 0.08 0.06 0.93 0.82 0.72 0.52 0.44 0.41
Total Noncurrent Assets
1.09 0.61 0.65 0.59 0.79 0.70 0.59 0.69 1.24 1.07
Other Noncurrent Operating Assets
1.09 0.61 0.65 0.59 0.79 0.70 0.59 0.69 1.24 1.07
Total Liabilities & Shareholders' Equity
130 85 79 78 100 86 73 199 179 167
Total Liabilities
15 3.40 1.85 3.63 9.23 7.90 6.41 14 7.25 9.34
Total Current Liabilities
14 2.81 1.35 3.25 8.79 7.60 6.25 14 6.64 8.79
Accounts Payable
2.47 0.68 0.06 0.24 2.34 2.38 5.68 14 6.31 8.54
Other Current Liabilities
0.33 0.33 0.33 0.29 0.55 0.56 0.57 0.41 0.34 0.25
Total Noncurrent Liabilities
1.88 0.58 0.50 0.38 0.45 0.31 0.16 0.01 0.60 0.55
Other Noncurrent Operating Liabilities
0.81 0.58 0.49 0.38 0.45 0.31 0.16 0.01 0.60 0.55
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
115 81 77 74 91 78 66 184 172 158
Total Preferred & Common Equity
115 81 77 74 91 78 66 184 172 158
Total Common Equity
115 81 77 74 91 78 66 184 172 158
Common Stock
305 308 309 310 261 264 267 414 417 420
Retained Earnings
-191 -227 -232 -236 -171 -186 -201 -229 -245 -263
Accumulated Other Comprehensive Income / (Loss)
-0.02 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01 -0.03

Annual Metrics And Ratios for OnKure Therapeutics

This table displays calculated financial ratios and metrics derived from OnKure Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 24,423,900.00 24,529,646.00 33,311,787.00 13,339,417.00 13,548,199.00
DEI Adjusted Shares Outstanding
0.00 24,423,900.00 24,529,646.00 33,311,787.00 13,339,417.00 13,548,199.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -1.63 -2.12 -1.06 -3.95 -4.39
Growth Metrics
- - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -102.32% -33.32% 30.96% -47.31% -15.93%
EBIT Growth
0.00% -103.41% -30.64% 28.91% -47.25% -15.75%
NOPAT Growth
0.00% -103.65% -35.24% 31.41% -47.25% -15.75%
Net Income Growth
0.00% -104.32% -30.64% 32.04% -49.17% -12.99%
EPS Growth
0.00% 77.19% 3.20% -5,768.40% 87.72% 71.20%
Operating Cash Flow Growth
0.00% -104.91% -24.69% 27.06% -47.97% -1.39%
Free Cash Flow Firm Growth
0.00% 0.00% -22.03% 32.04% -31.26% -45.72%
Invested Capital Growth
0.00% 82.15% -124.02% -57.36% -266.24% 58.66%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% -11.98% -7.60% 49.11% -435.66% 6.83%
EBIT Q/Q Growth
0.00% -12.20% -6.11% 45.23% -273.27% 6.78%
NOPAT Q/Q Growth
0.00% -12.33% -7.89% 49.14% -273.27% 6.78%
Net Income Q/Q Growth
0.00% -12.29% -6.11% 47.64% -215.26% 6.21%
EPS Q/Q Growth
0.00% 0.00% 0.00% -1,561.01% 93.33% -104.73%
Operating Cash Flow Q/Q Growth
0.00% -13.81% -13.39% 41.98% -178.11% 18.60%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -14.18% 43.06% -81.30% -4.60%
Invested Capital Q/Q Growth
0.00% 64.81% 70.19% 82.26% -161.62% 26.57%
Profitability Metrics
- - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
99.56% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 95.61% 96.85% 94.55%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-38.46% -40.21% -42.04% -55.19% -79.92% -74.39%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
32.01% -21.36% -42.04% 0.81% -1.20% -74.39%
Return on Equity Simple (ROE_SIMPLE)
46.22% -27.02% -51.97% 34.67% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-14 -28 -38 -26 -38 -44
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-10.78% -11.82% -11.46% -14.43% -20.77% -18.20%
Return On Investment Capital (ROIC_SIMPLE)
- - - 25.39% -36.67% -78.43%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-20 -40 -52 -37 -54 -63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-20 -40 -53 -36 -54 -62
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 1.42 0.57 0.00 1.10 0.70
Price to Tangible Book Value (P/TBV)
0.00 1.42 0.57 0.00 1.10 0.70
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.06 -1.02 -1.01 -1.02 -1.07 -1.06
Leverage Ratio
1.09 1.06 1.06 1.12 1.14 1.11
Compound Leverage Factor
1.09 1.06 1.06 1.08 1.11 1.05
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
183.22% 0.00% 0.00% 463.94% 0.00% 0.00%
Common Equity to Total Capital
-83.22% 100.00% 100.00% -363.94% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
10.97 17.92 1.92 0.00 3.84 -3.14
Noncontrolling Interest Sharing Ratio
183.22% 46.87% 0.00% 101.46% 98.49% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
12.01 24.79 14.93 4.64 10.73 10.28
Quick Ratio
11.71 23.81 14.20 4.10 10.52 9.97
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -30 -37 -25 -33 -48
Operating Cash Flow to CapEx
-77,233.33% -19,183.33% -13,688.44% -14,043.09% -98,301.92% -112,669.57%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-3.01 -0.54 -1.20 -1.89 -6.93 -2.87
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 2.47 -0.67 -0.69 -5.04 4.07
Enterprise Value (EV)
133 61 -44 0.00 3.96 -20
Market Capitalization
94 209 57 0.00 115 39
Book Value per Share
($20.76) $6.03 $4.08 ($3.06) $7.78 $4.15
Tangible Book Value per Share
($20.76) $6.03 $4.08 ($3.06) $7.78 $4.15
Total Capital
51 147 100 28 104 56
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-54 -148 -101 -30 -111 -59
Capital Expenditures (CapEx)
0.02 0.20 0.35 0.25 0.05 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.17 -0.14 -1.94 -3.40 -8.29 -4.13
Debt-free Net Working Capital (DFNWC)
50 148 99 26 102 55
Net Working Capital (NWC)
50 148 99 26 102 55
Net Nonoperating Expense (NNE)
5.78 12 14 9.46 15 15
Net Nonoperating Obligations (NNO)
-54 -148 -101 -30 -111 -59
Total Depreciation and Amortization (D&A)
0.02 0.25 -0.73 0.56 0.80 0.83
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($2.19) ($2.12) ($2.52) ($15.28) ($4.40)
Adjusted Weighted Average Basic Shares Outstanding
0.00 18.14M 24.50M 30.68M 3.45M 13.52M
Adjusted Diluted Earnings per Share
$0.00 ($2.19) ($2.12) ($2.52) ($15.28) ($4.40)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 18.14M 24.50M 30.68M 3.45M 13.52M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 24.46M 25.11M 33.42M 13.44M 13.67M
Normalized Net Operating Profit after Tax (NOPAT)
-14 -28 -38 -26 -38 -44
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% -8.21% -0.06%

Quarterly Metrics And Ratios for OnKure Therapeutics

This table displays calculated financial ratios and metrics derived from OnKure Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
33,420,808.00 33,420,808.00 33,428,808.00 13,339,417.00 13,435,826.00 13,510,399.00 13,529,961.00 13,548,199.00 13,673,565.00 40,395,480.00 40,496,309.00
DEI Adjusted Shares Outstanding
33,420,808.00 33,420,808.00 33,428,808.00 13,339,417.00 13,435,826.00 13,510,399.00 13,529,961.00 13,548,199.00 13,673,565.00 40,395,480.00 40,496,309.00
DEI Earnings Per Adjusted Shares Outstanding
-0.29 -0.42 -0.35 -1.31 -1.19 -1.14 -1.09 -1.00 -1.11 -0.38 -0.44
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
38.87% 31.53% 45.73% -173.61% -73.43% -13.51% -36.22% 24.65% 8.20% -3.72% -25.56%
EBIT Growth
34.92% 26.56% 40.03% -188.56% -72.92% -13.81% -34.65% 24.47% 8.15% -3.52% -24.84%
NOPAT Growth
39.03% 31.83% 44.89% -161.99% -72.92% -13.81% -34.65% 24.47% 8.15% -3.52% -24.84%
Net Income Growth
36.88% 27.61% 39.80% -194.16% -67.00% -8.85% -27.20% 22.58% 4.82% 0.29% -21.41%
EPS Growth
-4,961.67% -6,795.38% -543.49% 182.11% 96.08% 97.46% 97.02% -101.02% 6.72% 72.81% 66.97%
Operating Cash Flow Growth
-17.47% 59.83% 43.19% -348.90% -31.76% -105.07% -22.29% 50.71% 7.62% 22.00% -0.35%
Free Cash Flow Firm Growth
-51.27% -180.26% -101.32% -136.92% 37.62% 70.45% 40.31% -73.35% -22.87% -111.81% -23.79%
Invested Capital Growth
76.23% 101.92% 75.16% -266.24% -277.46% -2,770.77% -47.28% 58.66% -28.94% 17.86% -42.66%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-138.56% -46.63% 20.88% -64.54% 9.15% 4.03% 5.06% 8.98% -10.69% -8.43% -14.94%
EBIT Q/Q Growth
-146.56% -45.90% 19.74% -62.44% 9.09% 3.98% 5.04% 8.88% -10.55% -8.22% -14.51%
NOPAT Q/Q Growth
-132.59% -45.90% 19.74% -62.44% 9.09% 3.98% 5.04% 8.88% -10.55% -8.22% -14.51%
Net Income Q/Q Growth
-151.48% -48.27% 18.27% -50.93% 8.70% 3.36% 4.49% 8.14% -12.25% -1.25% -16.29%
EPS Q/Q Growth
74.15% -47.58% 18.45% 363.91% -101.23% 4.20% 4.39% 10.09% -13.27% 72.07% -16.13%
Operating Cash Flow Q/Q Growth
-213.28% 39.10% -64.70% -119.06% 40.03% 5.22% 1.79% 11.70% -12.39% 19.97% -26.35%
Free Cash Flow Firm Q/Q Growth
-154.99% -69.99% 21.12% 49.93% 7.08% 19.47% -59.33% -45.39% 34.14% -38.83% 6.89%
Invested Capital Q/Q Growth
15.85% 112.24% -1,458.97% -161.62% 13.27% 13.39% 25.06% 26.57% -170.52% 44.82% -30.15%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
97.00% 98.58% 100.38% 93.27% 93.68% 94.28% 94.83% 95.60% 97.07% 90.81% 92.22%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-35.34% -23.26% -17.68% -79.92% -68.72% -77.81% -90.36% -74.39% -42.73% -46.91% -55.18%
Cash Return on Invested Capital (CROIC)
0.00% -13,900.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-35.34% -23.26% -17.68% -1.20% -68.72% -77.81% -90.36% -74.39% -42.73% -46.91% -55.18%
Return on Equity Simple (ROE_SIMPLE)
-36.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.88 -10 -8.06 -13 -12 -11 -11 -9.89 -11 -12 -14
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-3.01% -3.74% -3.46% -6.19% -4.48% -4.95% -5.24% -4.26% -2.93% -2.71% -3.68%
Return On Investment Capital (ROIC_SIMPLE)
-8.47% -13.06% -10.89% -12.61% -13.13% -14.62% -16.33% -17.60% -5.93% -6.87% -8.59%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-9.83 -14 -12 -19 -17 -16 -16 -14 -16 -17 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.68 -14 -11 -18 -17 -16 -15 -14 -15 -17 -19
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 1.10 0.64 0.41 0.56 0.70 0.31 1.07 0.70
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 1.10 0.64 0.41 0.56 0.70 0.31 1.07 0.70
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.05 -1.05 -1.07 -1.07 -1.04 -1.03 -1.05 -1.06 -1.05 -1.04 -1.04
Leverage Ratio
1.09 1.08 1.10 1.14 1.07 1.06 1.07 1.11 1.09 1.06 1.07
Compound Leverage Factor
1.06 1.07 1.11 1.07 1.01 1.00 1.02 1.06 1.05 0.96 0.99
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 4.86 1.87 -0.13 0.00 -0.54 1.60 14.18 5.63
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 98.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
29.82 57.86 23.71 10.73 11.18 11.13 11.45 10.28 13.78 26.75 18.84
Quick Ratio
29.44 56.88 23.60 10.52 11.00 10.97 11.26 9.97 13.41 26.55 18.58
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-12 -20 -16 -8.05 -7.48 -6.02 -9.60 -14 -9.19 -13 -12
Operating Cash Flow to CapEx
-118,100.00% -64,730.00% -59,227.78% -155,693.33% -77,805.56% -102,107.69% -217,283.33% -127,911.11% -258,760.00% -345,133.33% -40,881.25%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -365.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 -242.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -242.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.59 0.20 -2.65 -6.93 -6.01 -5.21 -3.90 -2.87 -7.75 -4.28 -5.57
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
5.11 10 8.02 -5.04 -4.42 -5.40 -1.25 4.07 -1.74 0.93 -1.67
Enterprise Value (EV)
0.00 0.00 0.00 3.96 -39 -51 -33 -20 -135 7.82 -53
Market Capitalization
0.00 0.00 0.00 115 58 32 37 39 57 184 110
Book Value per Share
$2.43 $2.30 $2.21 $7.78 $6.75 $5.79 $4.91 $4.15 $13.48 $4.26 $3.90
Tangible Book Value per Share
$2.43 $2.30 $2.21 $7.78 $6.75 $5.79 $4.91 $4.15 $13.48 $4.26 $3.90
Total Capital
81 77 74 104 91 78 66 56 184 172 158
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-83 -77 -77 -111 -97 -83 -70 -59 -192 -176 -163
Capital Expenditures (CapEx)
0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.00 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.72 -0.03 -2.92 -8.29 -7.27 -6.42 -5.05 -4.13 -8.95 -5.35 -6.50
Debt-free Net Working Capital (DFNWC)
81 77 74 102 89 77 65 55 183 171 157
Net Working Capital (NWC)
81 77 74 102 89 77 65 55 183 171 157
Net Nonoperating Expense (NNE)
2.65 4.10 3.50 4.35 4.03 3.96 3.85 3.62 4.23 3.52 4.30
Net Nonoperating Obligations (NNO)
-83 -77 -77 -111 -97 -83 -70 -59 -192 -176 -163
Total Depreciation and Amortization (D&A)
0.15 0.15 0.28 0.22 0.21 0.21 0.20 0.20 0.20 0.19 0.14
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.25) ($0.16) ($1.10) $96.46 ($1.19) ($1.14) ($1.09) ($0.98) ($1.11) ($0.31) ($0.36)
Adjusted Weighted Average Basic Shares Outstanding
33.42M 33.42M 3.34M 3.45M 13.42M 13.51M 13.53M 13.52M 13.67M 49.87M 49.93M
Adjusted Diluted Earnings per Share
($0.25) ($0.16) ($1.10) $96.46 ($1.19) ($1.14) ($1.09) ($0.98) ($1.11) ($0.31) ($0.36)
Adjusted Weighted Average Diluted Shares Outstanding
33.42M 33.42M 3.34M 3.45M 13.42M 13.51M 13.53M 13.52M 13.67M 49.87M 49.93M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
33.42M 33.43M 13.34M 13.44M 13.51M 13.53M 13.55M 13.67M 40.40M 40.50M 40.50M
Normalized Net Operating Profit after Tax (NOPAT)
-6.88 -10 -8.06 -13 -12 -11 -11 -9.89 -11 -12 -14
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -261.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 -183.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 -262.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 -183.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -8.21% -7.39% -7.24% -6.88% -0.06% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

OnKure Therapeutics remains a development-stage biotechnology company with no reported revenue across the periods provided. Its financial profile is therefore driven primarily by research spending, equity financing and cash preservation rather than operating income.

  • Strong liquidity position: As of June 30, 2026, OnKure held $166.5 million in cash and equivalents plus $9.9 million in short-term investments, for total near-term liquidity of approximately $176.4 million.
  • Limited balance-sheet leverage: Total liabilities were $7.2 million compared with $172.1 million of equity. The company’s current assets of $177.7 million substantially exceeded current liabilities of $6.6 million.
  • Recent financing improved funding: OnKure issued approximately $146.0 million of common equity in the first quarter of 2026. That financing increased cash from $70.3 million at September 30, 2025, to $192.1 million at March 31, 2026.
  • Operating cash burn eased sequentially: Net cash used in operating activities improved from $12.9 million in Q1 2026 to $10.4 million in Q2 2026. The Q2 operating burn was also below the $13.0 million used in Q3 2025 and the $11.5 million used in Q4 2025.
  • Cash runway remains dependent on clinical spending: Using Q2 operating cash usage of $10.4 million as a rough quarterly benchmark, the company’s cash and short-term investments could support approximately four years of operations before considering changes in spending, financing, investments or clinical milestones. This is not a forecast, and the runway could shorten as development programs advance.
  • Investing activity is not currently a major cash drain: Capital expenditures were only $3,000 in Q2 2026 and $5,000 in Q1. The larger Q2 investing outflow of $9.9 million appears to reflect investment activity rather than significant spending on property and equipment.
  • No revenue or commercial earnings: Quarterly revenue has remained at $0, leaving the company with a gross profit of $0 and no operating source of cash. OnKure continues to rely on its cash balance and external financing to fund operations.
  • Losses remain substantial: Q2 2026 net loss was $15.3 million, compared with $15.2 million in Q1 2026 and $13.5 million in Q4 2025. The company has accumulated a retained-earnings deficit of $244.7 million.
  • Research and development spending is rising: R&D expense increased to $12.6 million in Q2 2026 from $11.7 million in Q1 and $10.1 million in Q3 2024. Total operating expenses reached $16.9 million in Q2, up from $15.6 million in Q1 and $14.1 million in Q4 2025.
  • Financing and dilution remain key risks: The large equity raise in Q1 2026 strengthened liquidity but increased the weighted-average basic share count from 13.7 million in Q4 2025 to 49.9 million in Q2 2026. In Q2, the company also repaid $9.6 million of debt while issuing only $4.2 million of common equity, contributing to a $25.6 million decline in cash and equivalents during the quarter.

Overall, OnKure’s balance sheet is substantially stronger than it was in mid-2024, when cash and short-term investments totaled approximately $78.7 million. However, the company continues to consume cash, report sizable losses and provide no revenue offset. For investors, the main financial considerations are the pace of clinical spending, the timing of potential development milestones and whether additional equity financing will be required before a product reaches commercialization.

11/21/26 06:23 PM ETAI Generated. May Contain Errors.

OnKure Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, OnKure Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

OnKure Therapeutics' net income appears to be on a downward trend, with a most recent value of -$59.52 million in 2025, falling from -$19.47 million in 2020. The previous period was -$52.67 million in 2024. See where experts think OnKure Therapeutics is headed by visiting OnKure Therapeutics' forecast page.

OnKure Therapeutics' total operating income in 2025 was -$62.95 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $62.95 million

Over the last 5 years, OnKure Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, OnKure Therapeutics' cash and equivalents has ranged from $11.74 million in Q3 2023 to $192.11 million in Q1 2026, and is currently $151.44 million as of their latest financial filing in Q3 2026.

OnKure Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, OnKure Therapeutics' book value per share changed from -20.76 in 2020 to 4.15 in 2025.



Financial statements for NASDAQ:OKUR last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners